Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1569-8041
    Keywords: alkylating agents ; bendamustine ; chemotherapy ; phase I study ; solid tumours ; weekly chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:The cytotoxic agent bendamustine combines apurine-like benzimidazol and alkylating nitrogen mustard group. The clinicallytolerated dose for single bolus bendamustine is 215 mg/m2, forfractionated therapy on four consecutive days 85 mg/m2. The maximumtolerated dose of a day 1 and 8 (q4w) 30 min infusion schedule was recentlyfound to be 160 mg/m2, mouth dryness and fatigue weredose-limiting. Our current phase I trial was designed to define therecommended dose of a new weekly short infusion schedule. Patients and methods:Patients with refractory malignant tumoursqualified for the trial after written informed consent was obtained.Bendamustine was given as a 30-min i.v. infusion weekly for up to eightconsecutive weeks. Results:Twelve patients (8 male, 4 female, median age 57.5 years,range 42–64) were enrolled in this trial. At the starting dose of 80mg/m2, two patients had dose-limiting toxicity (fatigue grade 3,mouth dryness grade 3, fever grade 4 Common Toxicity Criteria). Nodose-limiting events were observed in six patients treated at 60mg/m2. An intermediate dose level of 70 mg/m2 wasstudied in three younger, less heavily pre-treated patients, was welltolerated and not associated with dose-limiting events. Haematologicaltoxicity was mild except for grade 3–4 lymphocytopenia, occurring in 11of 12 patients. Bendamustine was found to induce long-lastingpanlymphocytopenia with predominant B-cell cytotoxicity. Conclusions:The maximum tolerated dose of weekly bendamustinegiven as a 30-min i.v. infusion is 80 mg/m2, mouth dryness, fatigueand fever are dose-limiting. The recommended dose for phase II trials is 60mg/m2.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1569-8041
    Keywords: chemotherapy ; gastric cancer ; oral fluoropyrimidine prodrug ; S-1 ; Tegafur
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We report the case of an unresected, metastatic gastric cancer, which was treated with a very short course of the oral 5-fluorouracil (5-FU) prodrug S-1. The patient had to discontinue chemotherapy during the first treatment cycle due to severe toxicity, but achieved a pathologically confirmed, long-term complete response of her primary tumour, a diffuse-type poorly differentiated adenocarcinoma.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-1335
    Keywords: Key words Bendamustine ; Alkylating agents ; Chemotherapy ; Phase I study ; Solid tumours ; AbbreviationsCMF cyclophosphamide, methotrexate, 5-fluorouracil
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: The cytotoxic agent bendamustine combines a purine-like benzimidazol and bifunctionally alkylating nitrogen mustard group. The drug has clinical antitumour activity in lymphoma, myeloma and breast cancer. In earlier dose-finding studies, the clinically tolerated dose for single-bolus bendamustine was 215 mg/m2; for fractionated therapy on 4 consecutive days it was 85 mg/m2. Anticholinergic symptoms, myelosuppression and cardiac dysrhythmia were dose-limiting. Our trial was designed to define the maximum tolerated dose of a short infusion schedule and to establish a recommended dose for ongoing and future clinical studies. Methods: Patients with refractory malignant tumours qualified for the trial after written informed consent had been obtained. Bendamustine was given as a 30-min iv. infusion on days 1 and 8 of a 4 week cycle, with a starting dose of 100 mg/m2 and an increment per group of 20 mg/m2. Results: Nineteen patients (13 male, 6 female; median age 57 years, range 37–74 years) were treated for one to two cycles with up to 180 mg/m2 bendamustine. At 160 mg/m2, fatigue grade 3 (NCI Common Toxicity Criteria) and dryness of the mouth grade 3 occurred in 2 patients, diarrhoea grade 3 in 1 patient; another patient with a history of myocardial infarction and arrhythmia developed a reversible total atrioventricular block after the first administration of 160 mg/m2 bendamustine. Other events, such as nausea/vomiting, loss of appetite, fever or chills, were not dose-limiting. Haematological toxicity was mild, except for sudden and long-lasting grade 3–4 lymphocytopenia, which occurred in all treatment cycles. Opportunistic infections were not observed. Conclusions: The maximum tolerated dose of a days-1 and -8 schedule of bendamustine, given as a 30-min i.v. infusion, is 160 mg/m2; mouth dryness and fatigue are dose-limiting. The recommended dose for future trials is 140 mg/m2.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 69 (1991), S. 344-344 
    ISSN: 1432-1440
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1432-1440
    Keywords: Recombinant human erythropoietin ; Stem cells ; Megakaryopoiesis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Recombinant human erythropoietin (rhEpo), now available, might become increasingly more important for clinical use, e.g., in the treatment of anemia of chronic renal failure. As a prerequisite of clinical trials, we analyzed the stimulatory and suppressive effects of rhEpo on human hemopoiesis by adding rhEpo to in vitro cultures of nonadherent low-density bone marrow cells obtained from normal persons and from patients undergoing hemodialysis for chronic renal failure. rhEpo was shown to be an effective stimulus for erythroid and multilineage colony formation. The dose-response curve was similar for erythroid progenitors BFU-E from normal controls and patients with chronic renal failure. rhEpo had no effect on megakaryocytic colony formation nor on the megakaryocytic differentiation of multilineage stem cells. Because of a good stimulatory activity on erythroid and multilineage stem cells and lack of toxic effects, rhEpo might be useful in the treatment of certain kinds of anemia.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Der vorgestellte Fallbericht beschreibt den klinischen Verlauf einer Patientin mit einer Reihe benigner Erkrankungen sowie einem Nierenzellkarzinom beidseits, einem Osteosarkom des Beckenknochens und einem Mammakarzinom. Der mögliche Kausalzusammenhang zwischen multiplen Erkrankungen der Patientin und der intravenösen Behandlung mit einem radioaktiven Medikament im Kindesalter wird dargestellt.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Electronic Resource
    Electronic Resource
    Springer
    Der Onkologe 4 (1998), S. 791-797 
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Bei den akuten myeloischen Leukämien (AML) handelt es sich um heterogene, maligne Erkrankungen des hämatopoetischen Systems, denen die maligne Transformation einer hämatopoetischen Vorläuferzelle zugrunde liegt [9]. Folge dieser Transformation ist ein Verlust oder die Einschränkung des Differenzierungspotentials der Zellen mit einem Ausreifungsstop auf einem frühen Stadium der Myelopoese. Bei erhaltener Proliferationskapazität kommt es zur klonalen Expansion der malignen Zellen mit sukzessiver „Verdrängung” der normalen Hämatopoese, an deren Folgen der Patient unbehandelt innerhalb weniger Wochen verstirbt. Haupttodesursachen sind Blutungen und /oder Infektionen.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1435-1420
    Keywords: Key words Bone marrow transplantation ; respiratory failure ; mechanical ventilation ; patient outcome assessment ; Score Systems ; Schlüsselwörter Knochenmark- ; transplantation ; Respiratorische Insuffizienz ; Beatmung ; Score Systeme
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die Prognose von Patienten, die mit malignen Erkrankungen auf Intensivstationen behandelt werden müssen, ist schlecht. Die Krankenhausmortalität von beatmeten onkologischen Patienten reicht von 70–90% bei Patienten mit soliden Tumoren zu 75–90% bei Patienten mit hämatologischen Neoplasien und bis zu 95% bei Patienten nach Knochenmarktransplantation. Durch Verbesserungen der allgemeinen onkologischen Therapien nimmt die Zahl der auf Intensivstationen verlegten onkologischen Patienten jedoch zu. Diese Situation führt immer wieder zu kontroversen Diskussionen über den Sinn intensivmedizinischer Therapien bei diesen Patienten. Da die individuelle Prognose der Patienten vor Einleitung der Intensivtherapie nicht verlässlich vorhergesagt werden kann, erscheint es nicht gerechtfertigt onkologischen Patienten generell eine intensivmedizinische Behandlung zu verwehren. Sinnvoll und praktikabel erscheint indes eine Reevaluation des Patienten nach Einleitung der Intensivtherapie zu vordefinierten Zeitpunkten und nach vordefinierten Kriterien. Für Patienten, die nach einer Knochenmarktransplantation beatmungspflichtig werden, gilt, daß die Patienten, die für längere Zeit mit Vasopressoren behandelt werden müssen und/oder ein kombiniertes Leber- und Nierenversagen entwickeln, nicht überleben werden. Für diese Patienten kann die Beendigung der intensivtherapeutischen Maßnahmen erwogen werden. Bei Patienten, die diese Kriterien nicht erfüllen, ist die Fortführung der Intensivtherapie sinnvoll. Die Therapieergebnisse sind denen bei nicht-onkologischen Patienten vergleichbar. Für andere Patienten mit onkologischen Erkrankungen kann die Anwendung eines neueren, speziell für onkologische Patienten entwickelten Score Systems Hilfestellung in der klinischen Entscheidung geben.
    Notes: Summary The prognosis of patients with malignant diseases requiring treatment on intensive care units is poor. The hospital mortality for mechanically ventilated patients ranges from 70–90% in patients with solid tumors to 75–90% in patients with hematological malignancy and up to 95% in patients after bone marrow transplantation. The number of patients referred to intensive care units is however increasing, due to improvements in the general treatment of malignant diseases. This results in controversies about the utilization of intensive care treatment in these patients. Since the individual outcome can not be predicted prior to initiation of intensive care therapy a general refusal of intensive care treatment seems not justified. A reevaluation of the patients status after initiation of intensive care treatment based on predefined criteria may however be useful in the decision about continuing intensive care measures. Patients requiring mechanical ventilation after bone marrow transplantation will not survive if prolonged treatment with vasopressors is necessary and/or sustained hepatic and renal failure is present. For these patients a withdrawal of further life support may be considered. Intensive care treatment should be continued in patients not fulfilling these criteria and treatment results are comparable to those in patients without malignant diseases. For other patients with malignant diseases the use of a new score system developed for patients with cancer can be helpful in the clinical decision making.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-0584
    Keywords: Myelofibrosis ; Chromosomal aberrations ; Circulating hemopoietic precursor cells ; Human placenta-conditioned medium
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Cytogenetic studies were performed on nine patients with myelofibrosis. Mononuclear cells from the peripheral blood were cultured for two days in the presence of human placenta-conditioned medium (HPCM) prior to the preparation of metaphases. Two patients showed abnormal clones. In one of them the Y chromosome was missing. In the other patient the abnormal clone was characterized by the involvement of the chromosomes 7 and 9 (46,XX,7q-,−9,+mar). The significance of cytogenetically abnormal circulating hemopoietic precursor cells in patients with myelofibrosis is discussed.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 1432-0584
    Keywords: Low-dose Ara-C ; Acute leukemia ; Differentiation induction
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The differentiation inducing effect of low-dose Ara-C on human myeloid leukemic cells was studied in two patients with subacute myelocytic and subacute myelomonocytic leukemia in vivo and in vitro. By continuous i. v. administration of 10 mg Ara-C/m2 over 12 h daily for 12 or 20 days complete remissions were obtained in both patients with normalization of the incidence of the comitted progenitor cells BFU-E and CFU-C in the marrow while the incidence of pluripotent CFU-GEMM remained subnormal. Parallel cultures of the patients' bone marrow cells in diffusion chambers (DC) implanted in mice demonstrated a clear cytotoxic effect of low-dose Ara-C. The greater increase of granulopoietic cells within DC in the Ara-C exposed group than in control mice after the end of drug administration is, in addition, an indication for differentiation induction by this kind of Ara-C therapy.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...